TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed metastatic (stage IV) NSCLC~* Measurable disease according to RECIST v.1.0 2009~* KRAS, BRAF and PI3K wild type in primary tumor or metastatic tissue.~* Age ≥18~* PS \< 2~* Adequate organ function~Haematology:~* Neutrophil count ≥1.5x10\^9/L~* Platelet count ≥100x10\^9/L~* Leucocyte count \> 3,000/mm~Hepatic function:~* Total bilirubin ≤ 1.5 times the upper normal limit (UNL)~* Serum transaminases ≤ 2.5xUNL in absence of liver metastases, or ≤ 5xUNL in presence of liver metastases~Renal Function:~* Creatinine clearance ≥ 50 mL/min and serum creatinine ≤ 1.5xUNL~Metabolic function:~* Magnesium ≥ lower limit of normal.~* Calcium ≥ lower limit of normal.~Consent to translational research studies~Written informed consent~Exclusion Criteria:~* Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year before enrollment/randomization, active severe infections or other concurrent disease.~* Known CNS metastasis (pretreatment routine assessment not required)~* Prior chemotherapy for metastatic disease~* Indication for radiation therapy or prior radiotherapy within 30 days before treatment start.~* Other malignant diseases within 5 years prior to inclusion in the study, except basal cell squamous carcinoma of the skin and cervical carcinoma-in-situ.~* Other experimental therapy within 30 days prior to treatment initiation.~* History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan.~* Patients pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment.~* Patients (male or female) not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months (male or female) after the end of treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Biopsy-confirmed relapsed, refractory, or progressive NHL or HL (Refer to Section 3.2.1 for excluded subtypes)~* At least 3 sites of disease~  1. One for diagnosis (lymph node or bone marrow biopsy)~ 2. One palpable for treatment~ 3. One measurable radiographically~* \> 60 days after RIC allogeneic transplant for lymphoma~* 18 years of age or older~* Mixed (5-95%) or complete (\>95%) chimerism~* Eastern Oncology Cooperative Group (ECOG) performance status ≤ 2~* ANC \>1000/mm3, platelets \>50,000/mm3~* Total bilirubin ≤ 2.5 mg/dL, AST and ALT \< 3 times upper limit of normal~* Serum creatinine ≤ 3 mg/dL~* No chemotherapy, RT, DLI or biologic therapy for lymphoma at least 4 weeks prior to scheduled treatment~* Minimal immunosuppression (defined as monotherapy with ≤ 10 mg prednisone daily, ≤ 200 mg cyclosporine daily, or ≤ 2 mg tacrolimus daily) at least 2 weeks prior to scheduled treatment~Exclusion Criteria:~* HIV associated lymphoma~* Acute GVHD at time of enrollment (history of treated and resolved GVHD is permitted)~* Active infection within 14 days prior to scheduled treatment~* Active Cytomegalovirus (CMV) disease at the time of enrollment~* Pre-existing autoimmune or antibody mediated disease (including systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, and autoimmune thrombocytopenia)~* Pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SD-101 + Combined with Local Radiation (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study to Evaluate Clinical Performance and Safety in Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18 - 80 years old at the time of the surgery~* Implanted (or with an indication) with an HLS KneeTec Cementless or hybrid fixation according to the Instructions for Use (IFU)~* Patients agree to consent to collect data from their medical records and agree to answer questionnaires for the purposes of the study.~Exclusion Criteria:~- Patients under guardianship and/or those who, according to the investigator or his delegated research team, will not be able to comply with the study procedures. (e.g. illiteracy, recent psychotic or manic disorders and/or inability to comply with routine follow-up visits.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Moderate Intensity Exercise and Phenylketonuria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* plasma phenylalanine concentration of \>1200 micromols at diagnosis~* treated by dietary phenylalanine restriction from early infancy~* willing to participate in this study~* stable BMI of 20-25 for the past 3 months~* currently in average to good physical fitness condition~* physically active 3-4 days per week~Exclusion Criteria:~* previously or are currently taking approved or experimental pharmacologic treatments (i.e.: Biopterin (BH4), sapropterin dihydrochloride (Kuvan), Large Neutral Amino Acids (LNAA), pegylated phenylalanine ammonia lyase (PEG-PAL))~* recent history of weight loss~* endocrine disorder~* pregnant~* anemic~* involved in any other study or research protocol~* participation in a current strength training or performance training regimen

- Gender: MALE
- Minimum Age: 14 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Sedentary Visit (Type: NO_INTERVENTION): Subjects will do quiet, sedentary activities for 8 hours. Hourly blood draws and breath sampling will be collected. Bolus C13-Lysine will be given at hour 4.
- Exercise Visit (Type: ACTIVE_COMPARATOR): Subjects will do quiet, sedentary activities until hour 5. Blood and breath samples will be collected. At hour 4, subject will consume a bolus of C13-Lysine and immediately walk on a treadmill at a moderate intensity (exercise at 75% of max heart rate) for 45 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Folic Acid on Endothelial and Baroreceptor Function in Patients With Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Heart failure (min. NYHA ll, LVEF \<50%)~* Not smokers~* Written informed consent~Exclusion Criteria:~* Unstable heart failure~* Smoking~* Unstabile Angina Pectoris~* Endocrinologic disease such as Diabetes mellitus, Hypo- und Hyperthyroidism~* Alcohol abuse~* Epilepsia~* Treatment with folic acid antaponists Trimethoprim, Pyrimethamin, Methotrexat..~* Participation to one other clinical Study within 1 Month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of Pathophysiological Mechanisms and Bronchial Response in Occupational Asthma to Wheat Flour and Quaternary Ammonium Compounds During Standardized Bronchial Provocation Tests

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~For patients with occupational asthma to wheat flour:~* Clinical history,~* A positive skin test to wheat flour and / or specific IgE to wheat flour~For patients with occupational asthma to quaternary ammonium compounds:~-Clinical history,~For two types of asthma:~* Patients must have a worsening of bronchial hyperreactivity during work compared to a rest period assessed by a metacholine challenge~* FEV before challenge (nonspecific and specific) must be\> 70%.~Exclusion Criteria:~Asthmas:~* no occupational asthma:~* secondary to clinically relevant sensitization to an allergen domestic~* aggravated at work.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- flour allergen extract or quaternary ammonium compound (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Alterations of Blood Clotting With the Use of Sequential Compression Devices on the Lower Limbs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elective major abdominal surgery for neoplasm~* Planned admission to postsurgical ICU due to the patient's meeting one or more of the following:~  * ASA Physical Status Class 4~ * Surgery of modified Johns-Hopkins class ≥IV~ * ASA 3 with modified Johns-Hopkins class 3 surgery~ * Expected duration of surgery ≥8 h~Exclusion Criteria:~* History of coagulation abnormalities, either congenital or acquired~* Ongoing treatment with anticoagulants/antiplatelet agents other than LMWH or hormones~* Massive edema of the legs~* Severe peripheral arteriopathy or neuropathy~* Malformations or recent surgery/trauma to the lower extremities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SCD + LMWH (Type: EXPERIMENTAL): This group will receive sequential compression device therapy to the lower limbs from their ICU admission until the morning after surgery.
- LMWH only (Type: ACTIVE_COMPARATOR): Patients in this group will receive only standard LMWH therapy during their ICU stay.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Non-invasive Home Ventilation in Patients With Severe Hypercapnic Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CROSSOVER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of COPD using Gold 2017 criterion~* Optimal medical treatment of COPD, ie. inhaled steroids, long-acting β2-agonist, long-acting anticholinergic, according to GOLD 2017 guidelines.~* At least one acute exacerbation of COPD with hypercapnic respiratory failure~* Introduction of NIV distant to acute exacerbation of COPD with persisting hypercapnia (\> 7kPa) on arterial blood gas at rest.~* NIV equipment from the service provider Don Du Souffle (DDS).~* Patient able to give their consent~Exclusion Criteria:~* Contraindication to NIV (consensus conference of SFAR-SPLF-SRLF)~* Obstructive sleep apnea with apnea/hypopnea index \> to 20/h~* BMI \> 35 kg/m2~* Low compliance with NIV treatment (\<3h per day)~* Acute exacerbation COPD during inclusion or pH \<7.30 in routine blood gas arterial~* Severe heart failure (New York Heart Association stage IV/IV)~* Unstable angina~* Severe arrhythmias~* Severe renal insufficiency stage \> 4~* Other conditions than COPD resulting in hypercapnia~* Pregnancy~* Patient without health insurance~* Patient excluded by another study

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- standard mode (Type: None): after adjusting pressure and different modes of ventilation to each individual patient. Each one of them will receive NIV using Löwenstein mode during one night at home. Patients will be under transcutaneous PCO2 measurement and polysomnographic surveillance.
- Lowenstein mode (Type: None): after adjusting pressure and different modes of ventilation to each individual patient. Each one of them will receive NIV without Löwenstein mode during one night at home. Patients will be under transcutaneous PCO2 measurement and polysomnographic surveillance.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Brain MRI-confirmed 1-10 solid tumor brain metastases~2. Biopsy-confirmed primary malignancy~3. ds-GPA estimated median survival of at least 6 months, for histologies not included in the ds-GPA, publications or noted online at brainmetgpa.com, the PI will use either published or validated data or their best clinical judgment to determine the patient's expected survival~4. Stereotactic radiosurgery candidate per treating Radiation Oncologist~5. ≥ 18 years old at the time of informed consent~6. Ability to provide written informed consent and HIPAA (Health Insurance Portability and Accountability Act) authorization.~7. ALC \> 800/ul (Ku et al., 2010)~8. Patients currently on cytotoxic chemotherapy are eligible~9. Patients receiving ICI up to 30 days prior to delivery of SRS are eligible~10. Patients having undergone operative resection for metastatic brain disease within 30 days of immune checkpoint inhibitor (ICI) administration are eligible.~Exclusion Criteria:~1. Major medical illnesses or psychiatric impairments, which in the investigator's opinion will prevent administration or completion of the protocol therapy and/or interfere with follow-up~2. Patients unable to receive MRI Brain~3. Patients with more than 10 brain metastases on MRI Brain imaging~4. Any lesion \> 4 centimeter maximum diameter~5. Total volume of metastatic disease more than 30 cubic centimeters~6. Previous whole brain radiation therapy~7. For Cohort 1: Previous stereotactic radiosurgery where the 50% isodose line overlaps with current treatment field~8. For Cohort 2: Patients whose treatment will have a dose overlap within the target from prior treatments of 20% or greater~9. Already receiving chronic dexamethasone (chronic = \> 2 weeks) prior to SRS~10. Not a radiosurgical candidate per Radiation Oncology discretion~11. Existing autoimmune disease~12. Patients who have an unknown primary cancer~13. Histology not amenable for SRS (i.e. lymphoma). (Small Cell Lung Cancer IS amenable.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Reduced Dose Stereotactic Radiosurgery (Type: EXPERIMENTAL): Subjects will receive one stereotactic radiosurgery (SRS) treatment at a reduced dose based on the brain tumor size concurrently with their standard of care immunotherapy. Subjects will undergo follow up with clinical exams and brain MRI scans at 1, 3, 6, 9, and 12 months post SRS treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Hypersensitivity Syndrome (DRESS) With Tegeline® (Human Immunoglobulin)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \>= 18~* Cutaneous and/or mucous eruption~* Polyadenopathy~* Body temperature \> 38°C~* Hematology disorders : Hypereosinophily \> 1.5 G/l, lymphocytosis \> 5G/l, atypical blood lymphocytes~* Consent obtained from patient~Exclusion Criteria:~* Age \< 18~* No consent obtained from patient~* IgV allergy~* Dress with very sérious visceral attack and vital diagnostic (sharp cardiac insufficiency, sharp respiratory insufficiency, hepatic insufficiency, sharp renal insufficiency)~* Oral therapy or immunosuppressive therapy (Methotrexate, cyclosporine, cyclophosphamide, etc.)~* IgA deficiency,~* MCI \>=35~* Sharp renal insufficiency before Dress with creatinaemia \< 60 ml/min (Cockroft)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Probable Alzheimer's disease~* Mini Mental State Examination score 18-26 inclusive~* Aged 55-85~Exclusion Criteria:~* Dementia other than Alzheimer's disease~* Clinically significant cardiovascular disease in the past 6 months prior to screening~* Creatinine clearance \<30 mL/min

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- PF-03654746 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: His-pacing and AV-node Ablation vs. Pulmonary Vein Isolation for Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Indication for invasive treatment of symptomatic atrial fibrillation according to current guidelines~* LVEF \>35%~* Age 70-85 years~* Persistent atrial fibrillation, or paroxysmal atrial fibrillation with at least moderate enlargement of the left atrium (≥42ml/m2)~* Chronic and well-tolerated treatment with anticoagulants (either non-vitamin K oral anticoagulant or vitamin K antagonist)~* Willingness to participate, to understand the instructions and fill out the questionnaires, and ability to sign informed consent~Exclusion Criteria:~* Chronic atrial fibrillation with \>1 year duration~* BMI \>40kg/m2~* Hypertrophic cardiomyopathy~* Severe heart failure with symptoms ≥ NYHA class IIIb~* Heart amyloidosis~* Cardiac sarcoidosis~* Recent (\<3 months) myocardial infarction~* Significant heart valve disease (pronounced insufficiency or stenosis)~* Pacemaker or ICD treatment ongoing, or current pacemaker indication~* Congenital heart disease that required surgical correction~* Comorbidity that is assessed significantly affect the patient's quality of life over the next year, or 3-year survival

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Conduction System pacing plus AV node ablation (Type: EXPERIMENTAL): A His-pacing lead in combination with a backup RV pacing lead or an LBB pacing lead, and a right atrial lead (if needed) will be placed using standard technique. The His-pacing or LBB pacing lead will be Medtronic 3830, and the outer sheath will be either Medtronic C304 or C315 deflectable. If failure to implant with these tools, other leads and sheaths can be used at the discretion of the operator. A standard DDD pacemaker or CRT-P device from Medtronic will be used.~A minimum of three weeks post-implant, the device will be interrogated and His-bundle threshold will be evaluated. A threshold of ≤2.0V@1.0ms is acceptable. If the device is well-functioning and successful His-pacing is documented, AV node ablation will be performed.
- Pulmonary vein isolation (Type: ACTIVE_COMPARATOR): Atrial fibrillation will be performed as a complete pulmonary vein isolation. Either Cryoballon or radio frequency ablation with irrigated tip contact force enabled catheter can be used. Pulsed field ablation can be used if available. Endpoint is complete electrical isolation of all pulmonary veins, verified by entry- and exit block using a multipolar catheter during pacing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues